HOME >> BIOLOGY >> NEWS
ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML

s with the T315I Bcr-Abl mutation," said Greg Collier, Ph.D., Chief Executive Officer and Managing Director of ChemGenex.

ChemGenex is currently treating patients in two clinical studies that are designed to support the filing of New Drug Applications (NDAs) for the treatment with Ceflatonin of sub-sets of CML patients. The first study, is for Gleevec-resistant patients with the T315I point mutation and the complementary second study is for CML patients who are resistant to, or intolerant to treatment with two or more tyrosine kinase inhibitors.

"We believe that Ceflatonin offers significant potential as a therapeutic alternative for these unserved and growing CML patient populations," Dr Collier added.


'"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
11-Jun-2007


Page: 1 2

Related biology news :

1. ChemGenex reports successful personalized dosing of Quinamed at ASCO
2. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
3. ESA announces 2007 award recipients
4. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
5. Conservation Leadership Program announces 2007 awardees
6. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
7. Revolutionary global environment fund announces $50M expansion
8. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
9. Cell Press announces new partnership with the American Society of Human Genetics
10. Minister Lunn announces $39.6M for next phase of mountain pine beetle response
11. BioMed Central announces new interdisciplinary Biofuels Journal

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2020)... ... August 06, 2020 , ... Alucio™, a ... announce that Eric Chen and Jessica Wong have joined the company’s leadership team ... respectively. , Eric Chen heads development efforts for Alucio’s flagship product, Beacon, an ...
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received ... innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts to be assigned ... syringe. The company’s solutions are the first Wharton’s jelly allograft product to be recognized ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... II contract awarded by the Joint Science & Technology Office—Chemical and Biological Defense ... to develop, optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess suitable ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 30, 2020 , ... ... industry, today announced the release of its signature product called Beacon - ... (MSLs) and other field medical professionals. , Beacon helps MSLs streamline ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial ... early detection and prevention of high-burden diseases, and Centric Consulting, a business and ... organizations to utilize existing data in order to identify and prioritize patients for ...
(Date:7/10/2020)... ... 09, 2020 , ... In most research using the zebrafish ... formation in zebrafish embryos, maintaining optical transparency to facilitate microscopic imaging. Over the ... using the zebrafish model to investigate the causes of leukaemia and its relationship ...
(Date:7/1/2020)... ... 29, 2020 , ... MedShift , a leading medical ... many obstacles created as a result of COVID-19. As a provider at the ... practices and medical manufacturers by expanding access to device offerings, technology services, and ...
Breaking Biology Technology:
Cached News: